FDA clears Nurix Therapeutics, Inc.'s GS-6791 for inflammatory disorders; Nurix earns $5M milestone from Gilead. Click for my ...

Sanofi has returned to Nurix Therapeutics for another autoimmune candidate, paying $15 million and committing up to $465 million for exclusive rights to a degrader of a once-undruggable ...

Nurix is eligible for an additional $420 million in development, regulatory and commercial milestones associated with the ...

NX-5948 assigned the nonproprietary name “bexobrutideg”U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström ...

To date, Nurix has received $460 million from partners, including $105 million in payments received from the Sanofi collaboration. We look forward to continuing to advance these programs together ...

NX-5948 assigned the nonproprietary name "bexobrutideg"U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemiaAchieved $7M in milestones and a $15M ...

Nurix received a $15 million license extension fee from Sanofi under its 2019 collaboration agreement, bringing the total amount received by Nurix to date to $105 million Nurix is eligible for an ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

Nurix Therapeutics has widened its collaboration with Sanofi, granting the French pharmaceutical company an exclusive license to an undisclosed program targeting a previously undruggable ...

Nurix received a $15 million license extension fee from Sanofi under its 2019 collaboration agreement, bringing the total amount received by Nurix to date to $105 million Nurix is eligible for an ...